Compounds for diagnosis

A detectably labelled compound of formula (I)

• stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein
• is an aryl or a heteroaryl which is directionally selected from the group consisting of:
• R0 is H or C1-C4alkyl;
• R1 is —CN;
• or halo;
• or C1-C4alkyl;
• or C1-C4alkoxy:
• or —N(C1-C4alkyl)2;
• or —NH(C1-C4alkyl);
• or H;
• or
• R1 is —NH—C3-C6cycloalkyl, C3-C6cycloalkyl, or heterocyclyl, which is a 4- to 6-membered non-aromatic monocyclic ring radical containing 1 or 2 heteroatoms, each of which is optionally substituted with at least one halo;
• R2 is selected from the group consisting of:
• wherein
• R2a, R2a′ are independently H, or F;
• R2b is independently F, OH, C1-C4alkyl, haloC1-C4alkyl, NH2, CN, or C1-C4alkoxy;
• R2c, R2c′ are independently H, F, OH, OCH3, or CH3;
• R2d is H, F, or OH;
• R2e is H, OH, CH3, or F;
• Z is independently N, NH, N(C1-C4alkyl), N(haloC1-C4alkyl), O, or S;
• Z1 is independently N, NH, O, or S;
• p is 0, 1 or 2;
• m is 0 or 1;
• as valency permits, is a combination of single and double bonds;
• and
• * is the position of bonding,
• wherein the compound is a detectably labelled compound.

A compound selected from the group consisting of

• (A) a compound of formula (IV-F)
• or a stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof,
• wherein
• R3 is
• R4 is selected from the group consisting of:
• R2a, R2a′ are independently H, or F;
• R2b is independently F, —OH, C1-C4alkyl, haloC1-C4alkyl, —NH2, —CN, or C1-C4alkoxy;
• R2c, R2c′ are independently H, F, OH, OCH3, or CH3;
• R2d is H, F, or —OH;
• R2e is H, OH, CH3, or F;
• Z is independently N, NH, N(C1-C4alkyl), N(haloC1-C4alkyl), O, or S;
• Z1 is independently N, NH, O, or S;
• p is 0, 1 or 2;
• m is 0 or 1;
• as valency permits, is a combination of single and double bonds;
• and
• * is the position of bonding;
• (B) a compound of formula (IV-H)
• or a stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof,
• wherein
• R5 is
• R6 is selected from the group consisting of:
• wherein
• R2a, R2a′ are independently H, X or F;
• R2b is independently X, F, —OH, C1-C4alkyl, haloC1-C4alkyl, —NH2, —CN, or C1-C4alkoxy, and wherein C1-C4alkyl, haloC1-C4alkyl, or C1-C4alkoxy optionally comprise one or more X;
• R2c, R2c′ are independently X, H, F, OH, OCH3, or CH3;
• R2d is X, H, F, or —OH;
• R2e is X, H, OH, CH3, or F;
• Z is independently N, NH, N(C1-C4alkyl), N(haloC1-C4alkyl), O, or S;
• Z1 is independently N, NH, O, or S;
• p is 0, 1 or 2;
• m is 0 or 1;
• as valency permits, is a combination of single and double bonds;
• * is the position of bonding;
• Fluoro is 19F;
• X is Bromo, Chloro, or Iodo;
• and
• wherein R6 comprises at least one X;
• (C) a compound of formula (IV-J)
• or a stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof,
• wherein
• R7 is
• R8 is selected from the group consisting of:
• wherein
• R2a, R2a′ are independently H, or F;
• R2b is independently F, —OH, C1-C4alkyl, haloC1-C4alkyl, —NH2, —CN, or C1-C4alkoxy;
• p is 0, 1 or 2;
• Rz is H, C1-C4alkyl or haloC1-C4alkyl;
• as valency permits, is a combination of single and double bonds;
• Fluoro is 19F;
• and
• * is the position of bonding.

A test kit for the detection and/or diagnosis of a disease, disorder or abnormality associated with alpha-synuclein aggregates, wherein the test kit comprises at least one compound of formula (I)

• or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof
• wherein
• is an aryl or a heteroaryl which is directionally selected from the group consisting of:
• R0 is H or C1-C4alkyl;
• R1 is —CN;
• or halo;
• or C1-C4alkyl;
• or C1-C4alkoxy;
• or —N(C1-C4alkyl)2;
• or —NH(C1-C4alkyl);
• or H;
• or
• R1 is —NH—C3-C6cycloalkyl, C3-C6cycloalkyl, or heterocyclyl, which is a 4- to 6-membered non-aromatic monocyclic ring radical containing 1 or 2 heteroatoms, each of which is optionally substituted with at least one halo;
• R2 is selected from the group consisting of:
• wherein
• R2a, R2a′ are independently H, or F;
• R2b is independently F, OH, C1-C4alkyl, haloC1-C4alkyl, NH2, CN, or C1-C4alkoxy;
• R2c, R2c′ are independently H, F, OH, OCH3, or CH3;
• R2d is H, F, or OH;
• R2e is H, OH, CH3, or F;
• Z is independently N, NH, N(C1-C4alkyl), N(haloC1-C4alkyl), O, or S;
• Z1 is independently N, NH, O, or S;
• p is 0, 1 or 2;
• m is 0 or 1;
• as valency permits, is a combination of single and double bonds;
• and
• * is the position of bonding.